Lipoprotein(a) and homocysteine potentiate the risk of coronary artery disease in male subjects

Circulation Journal

Volumn 76, Issue 8, 2012, Pages 1953-1957

  Baños González, Manuel Alfonso ^a,c,d   Anglés Cano, Eduardo ^e   Cardoso Saldaña, Guillermo ^a   Peña Duque, Marco Antonio ^a   Martínez Ríos, Marco Antonio ^a   Valente Acosta, Benjamin ^a,b   González Pacheco, Héctor ^a   de la Peña Díaz, Aurora ^b  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^c 86126 Villahermosa TAB   (Mexico)

^d UNIVERSIDAD JUÁREZ AUTÓNOMA DE TABASCO   (Mexico)

^e INSERM   (France)

Author keywords

Atherosclerosis; Coronary artery disease; Homocysteine; Lipoprotein(a)

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ANGIOCARDIOGRAPHY; ANTHROPOMETRY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; GENDER; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; RISK FACTOR; SMOKING;

AGED; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; HOMOCYSTEINE; HUMANS; LIPOPROTEIN(A); LOGISTIC MODELS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84864381313     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-0039     Document Type: Article

References (46)

1. Stary HC. Composition and classification of human atherosclerotic lesions. Virchows Arch 1992; 421: 277-290.
2. Libby P, Okamoto Y, Rocha VZ, Folco E. Inflammation in atherosclerosis: Transition from theory to practice. Circ J 2010; 74: 213-220.
3. Wald DS, Morris JK, Wald NJ. Reconciling the evidence on serum homocysteine and ischaemic heart disease: A meta-analysis. PLoS One 2011; 6: e16473.
4. Humphrey LL, Fu R, Rogers K, Freeman M, Helfand M. Homocysteine level and coronary heart disease incidence: A systematic review and meta-analysis. Mayo Clin Proc 2008; 83: 1203-1212.
5. de la Peña-Díaz A, Izaguirre-Avila R, Anglés-Cano E. Lipoprotein Lp(a) and atherothrombotic disease. Arch Med Res 2000; 31: 353-359.
6. Helfand M, Buckley DI, Freeman M, Fu R, Rogers K, Fleming C, et al. Emerging risk factors for coronary heart disease: A summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151: 496-507.
7. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302: 412-423.
8. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: Current status. Eur Heart J 2010; 31: 2844-2853.
9. Genser B, Dias KC, Siekmeier R, Stojakovic T, Grammer T, Maerz W. Lipoprotein (a) and risk of cardiovascular disease: A systematic review and meta analysis of prospective studies. Clin Lab 2011; 57: 143-156.
10. Gaubatz JW, Heideman C, Gotto AM, Morrisett JD, Dahlen GH. Human plasma lipoprotein [a]: Structural properties. J Biol Chem 1983; 258: 4582-4589.
11. Anglés-Cano E, de la Peña A, Loyau S. Inhibition of fibrinolysis by lipoprotein (a). Ann NY Acad Sci 2001; 936: 261-275.
12. Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein (a), fibrin binding, and plasminogen activation. Arteriosclerosis 1990; 10: 240-245.
13. Baños-Gonzalez MA, Peña-Duque MA, Angles-Cano E, Martinez-Rios MA, Bahena A, Valente-Acosta B, et al. Apo (a) phenotyping and long-term prognosis for coronary artery disease. Clin Biochem 2010; 43: 640-644.
14. Ikenaga H, Ishihara M, Inoue I, Kawagoe T, Shimatani Y, Miura F, et al. Usefulness of Lipoprotein (a) for predicting progression of non-culprit coronary lesions after acute myocardial infarction. Circ J 2011; 75: 2847-2852.
15. Tanriverdi H, Evrengul H. Effect of homocysteine-induced oxidative stress on endothelial function in coronary slow-flow. Cardiology 2007; 107: 313-320.
16. Ferreti G, Bacchetti T, Nègre-Salvayre A, Salvayre R, Dousset N, Curatola G. Structural modifications of HDL and functional consequences. Atherosclerosis 2006; 184: 1-7.
17. Dayal S, Bottiglieri T, Arning E, Maeda N, Malinow MR, Sigmund CD, et al. Endothelial dysfunction and elevation of S-adenosyl homocysteine in cystathionine β-synthase deficient mice. Circ Res 2001; 88: 1203-1209.
18. Boerwinkle E, Leffert C, Lin J, Lackner C, Chiesa G, Hobbs HH. Apolipoprotein (a) gene accounts for greater than 90% of the variation in plasma lipoprotein (a) concentrations. J Clin Invest 1992; 90: 52-60.
19. Wilcken B, Bamforth F, Li Z, Zhu H, Ritvanen A, Renlund M, et al. Geographical and ethnic variation of the 677C>T allele of 5,10 methylene tetrahydrofolate reductase (MTHFR): Findings from over 7000 newborns from 16 areas world wide. J Med Genet 2003; 40: 619-625.
20. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: A potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 1992; 89: 10193-10197.
21. Nardulli M, Durlach V, Pepe G, Anglés-Cano E. Mechanism for the homocysteine-enhanced antifibrinolytic potential of lipoprotein(a) in human plasma. Thromb Haemost 2005; 94: 75-81.
22. Foody JM, Milberg JA, Robinson K, Pearce GL, Jacobsen DW, Sprecher DL. Homocysteine and lipoprotein (a) interact to increase CAD risk in young men and women. Arterioscler Thromb Vasc Biol 2000; 20: 493-499.
23. Balogh E, Bereczky Z, Katona E, Köszegi Z, Edes I, Muszbek L, et al. Interaction between homocysteine and lipoprotein(a) increases the prevalence of coronary artery disease/myocardial infarction in women: A case-control study. Thromb Res 2012; 129: 133-138.
24. Foody JM, Milberg JA, Pearce GL, Sprecher DL. Lipoprotein (a) associated with coronary artery disease in older women: Age and gender analysis. Atherosclerosis 2000, 153: 445-451.
25. Valentine RJ, Kaplan HS, Green R, Jacobsen DW, Myers SI, Clagett GP. Lipoprotein (a), homocysteine, hypercoagulable states in young men with premature peripheral atherosclerosis: A perspective, controlled analysis. J Vasc Surg 1996; 23: 53-61.
26. Guéant-Rodriguez RM, Guéant JL, Debard R, Thirion S, Hong LX, Bronowicki JP, et al. Prevalence of methylenetetrahydrofolate reductase 677T and 1298C alleles and folate status: A comparative study in Mexican, West African, and European populations. Am J Clin Nutr 2006; 83: 701-707.
27. Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase, A2 activity, and 10-year cardiovascular outcomes: Prospective results from the Bruneck Study. Arterioscler Thromb Vasc Biol 2007; 27: 1788-1795.
28. Tsimikas S, Kiechl S, Willeit J, Mayr M, Miller ER, Kronenberg F, et al. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: Five-year prospective results from the Bruneck Study. J Am Coll Cardiol 2006; 47: 2219-2228.
29. Ariyo AA, Thach C, Tracy R, the Cardiovascular Health Study Investigators. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med 2003; 349: 2108-2115.
30. Prentice RL, Pyke R. Logistic disease incidence models and case-control studies. Biometrika 1979; 66: 403-411.
31. Van den Brandhof WE, Haks K, Schouten EG, Verhoef P. The relation between plasma cysteine, plasma homocysteine and coronary atherosclerosis. Atherosclerosis 2001; 157: 403-409.
32. Chambers JC, Obeid OA, Refsum H, Ueland P, Hackett D, Hooper J, et al. Plasma homocysteine concentrations and risk of coronary heart disease in UK Indian Asian and European men. Lancet 2000; 355: 523-527.
33. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-236.
34. Folsom AR, Nieto FJ, McGovern PG, Tsai MY, Malinow MR, Eckfeldt JH, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: The Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998; 98: 204-210.
35. Rodríguez JF, Escobales N, Cruz D, Banch H, Rivera C, Altieri PI. Total plasma homocysteine concentrations in Puerto Rican patients with ischemic heart disease. Rev Esp Cardiol 2001; 54: 1411-1416 (in Spanish).
36. Montaño-Loza AJ, Meza-Junco J, Valles-Sánchez VE, Castillo-Martínez L, Orea-Tejeda A. Plasma homocysteine concentrations in Mexican patients with ischemic heart disease. Rev Invest Clin 2004; 56: 580-585 (in Spanish).
37. Ruiz-Argüelles GJ, González-Carrillo ML, Estrada-Gómez R, Valdés-Tapia P, Parra-Ortega I, Porras-Juárez A. Primary thrombophilia in México. VI: Lack of statistical association among the inherited thrombophilic conditions. Gac Med Mex 2007; 143: 317-322.
38. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: Meta-analysis. JAMA 2002; 288: 2015-2022.
39. Pitla S, Nagalla B. Gender-related differences in the relationship between plasma homocysteine, anthropometric and conventional biochemical coronary heart disease risk factors in middle-aged Indians. Ann Nutr Metab 2009; 54: 1-6.
40. Powers RW, Majors AK, Lykins DL, Sims CJ, Lain KY, Roberts JM. Plasma homocysteine and malondialdehyde are correlated in an age-and gender-specific manner. Metabolism 2002; 51: 1433-1438.
41. Mayer O Jr, Simon J, Rosolová H. Gender differences in serum homocysteine levels and associated factors. Cas Lek Cesk 1999; 138: 525-527.
42. Russo GT, Friso S, Jacques PF, Rogers G, Cucinotta D, Wilson PW, et al; Framingham Offspring Study Cohort. Age and gender affect the relation between methylenetetrahydrofolate reductase C677T genotype and fasting plasma homocysteine concentrations in the Framingham Offspring Study Cohort. J Nutr 2003; 133: 3416-3421.
43. Papoutsakis C, Yiannakouris N, Manios Y, Papaconstantinou E, Magkos F, Schulpis KH, et al. The effect of MTHFR(C677T) geno-type on plasma homocysteine concentrations in healthy children is influenced by gender. Eur J Clin Nutr 2006; 60: 155-162.
44. Hervio L, Durlach V, Girard-Globa A, Anglés-Cano E. Multiple binding with identical linkage; a mechanism that explains the effect of lipoprotein(a) on fibrinolysis. Biochemistry 1995; 34: 13353-13358.
45. Kang C, Dominguez M, Loyau S, Miyata T, Durlach V, Anglés-Cano E. Lp(a) particles mold fibrin-binding properties of apo(a) in size-dependent manner: A study with different length recombinant apo(a), native Lp(a), and monoclonal antibody. Arterioscler Thromb Vasc Biol 2002; 22: 1232-1328.
46. De la Peña-Díaz A, Cardoso Saldaña G, Zamora-González J, Barinagarrementeria F, Loyau S, Izaguirre R, et al. Functional approach to investigate Lp(a) in ischaemic heart and cerebral diseases. Eur J Clin Invest 2003; 33: 99-105.